Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Vascul Pharmacol. 2021 Jun 9;139:106881. doi: 10.1016/j.vph.2021.106881

Figure 1. Ang-II treatment activates vascular inflammasome.

Figure 1.

Casp1- mediated specific fluorescent-labeled substrate (FLICA® 660) degradation (in red) is overlaid to the elastin autofluorescence (in green) in thoracic aortae (A) and FLICA® 660 quantification (B) from Ctrl (WT) and Ang-II treated mice (490 ng/min/kg for 14 days with ALZET osmotic minipumps). N= 3. Values are reported as mean ± s.e.m. *P <0.05 vs. WT.